POC Lipid Testing - Global Strategic Business Report

The global market for POC Lipid Testing was estimated at US$263.3 Million in 2023, and is projected to reach US$327.1 Million by 2030, growing at a CAGR of 3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Hyperlipidemia Application segment, which is expected to reach US$97.0 Million by 2030 with a CAGR of a 2.9%. The Hypertriglyceridemia Application segment is also set to grow at 4.1% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $69.2 Million in 2023, and China, forecasted to grow at an impressive 5.4% CAGR to reach $70.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global POC Lipid Testing Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global POC Lipid Testing Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global POC Lipid Testing Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as A. Menarini Industrie Farmaceutiche Riunite Srl, Abaxis, Inc., Accutech LLC, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

A. Menarini Industrie Farmaceutiche Riunite Srl
Abaxis, Inc.
Accutech LLC
Alere, Inc.
Biochemical Systems International Srl
Bio-Rad Laboratories, Inc.
Eurotrol B.V.
F. Hoffmann-La Roche AG
General Life Biotechnology Co., Ltd.
Helena Laboratories Corporation
Nova Biomedical Corporation

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
POC Lipid Testing - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Hyperlipidemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 9: World 16-Year Perspective for Hypertriglyceridemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 12: World 16-Year Perspective for Familial Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 13: World Recent Past, Current & Future Analysis for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 14: World Historic Review for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 15: World 16-Year Perspective for Hyperlipoproteinemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 17: World Historic Review for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 18: World 16-Year Perspective for Tangier Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 22: World POC Lipid Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 23: USA Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 24: USA Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 25: USA 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

CANADA

Table 26: Canada Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 27: Canada Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 28: Canada 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

JAPAN

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 29: Japan Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 30: Japan Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 31: Japan 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

CHINA

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 32: China Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 33: China Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 34: China 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

EUROPE

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 35: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 36: Europe Historic Review for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 37: Europe 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 38: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 39: Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 40: Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

FRANCE

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 41: France Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 42: France Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 43: France 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

GERMANY

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 44: Germany Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 45: Germany Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 46: Germany 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

ITALY

Table 47: Italy Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 48: Italy Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 49: Italy 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

UNITED KINGDOM

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 50: UK Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 51: UK Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 52: UK 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

SPAIN

Table 53: Spain Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 54: Spain Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 55: Spain 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

RUSSIA

Table 56: Russia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 57: Russia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 58: Russia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 59: Rest of Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 60: Rest of Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 61: Rest of Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

ASIA-PACIFIC

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 62: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 63: Asia-Pacific Historic Review for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 64: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 65: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 66: Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 67: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

AUSTRALIA

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl
Abaxis, Inc.
Accutech LLC
Alere, Inc.
Biochemical Systems International Srl
Bio-Rad Laboratories, Inc.
Eurotrol B.V.
F. Hoffmann-La Roche AG
General Life Biotechnology Co., Ltd.
Helena Laboratories Corporation
Nova Biomedical Corporation

Table Information

Report Attribute	Details
No. of Pages	192
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 263.3 Million
Forecasted Market Value ( USD ) by 2030	$ 327.1 Million
Compound Annual Growth Rate	3.1%
Regions Covered	Global
No. of Companies Mentioned	11

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4836EUR$4,950USD£4,038GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9189EUR$9,405USD£7,671GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14509EUR$14,850USD£12,113GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 42 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

POC Lipid Testing Market by Component, Indication, End-User - Global Forecast 2025-2030

2024 POC/Decentralized Lipid Testing Market: Country Supplier Shares, Test Volume and Sales Segment Forecasts

2024 POC Lipid Testing Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts - Physician Offices, ERs, Ambulatory Care Centers - Profiles of Leading Competitors

Lipid Panel Testing Global Market Report 2024

POC Cholesterol Test Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)